AU2007294293B2 - Ip-10 based immunological monitoring - Google Patents

Ip-10 based immunological monitoring Download PDF

Info

Publication number
AU2007294293B2
AU2007294293B2 AU2007294293A AU2007294293A AU2007294293B2 AU 2007294293 B2 AU2007294293 B2 AU 2007294293B2 AU 2007294293 A AU2007294293 A AU 2007294293A AU 2007294293 A AU2007294293 A AU 2007294293A AU 2007294293 B2 AU2007294293 B2 AU 2007294293B2
Authority
AU
Australia
Prior art keywords
antigen
level
sample
test
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007294293A
Other languages
English (en)
Other versions
AU2007294293A1 (en
Inventor
Jesper Eugen-Olsen
Pernille Ravn
Morten Ruhwald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Statens Serum Institut SSI
Original Assignee
Statens Serum Institut SSI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Serum Institut SSI filed Critical Statens Serum Institut SSI
Publication of AU2007294293A1 publication Critical patent/AU2007294293A1/en
Priority to AU2012244350A priority Critical patent/AU2012244350B2/en
Application granted granted Critical
Publication of AU2007294293B2 publication Critical patent/AU2007294293B2/en
Assigned to Statens Serun Institut reassignment Statens Serun Institut Request for Assignment Assignors: HVIDOVRE HOSPITAL
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56927—Chlamydia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/295—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Chlamydiales (o)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Jellies, Jams, And Syrups (AREA)
AU2007294293A 2006-09-05 2007-09-05 Ip-10 based immunological monitoring Active AU2007294293B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012244350A AU2012244350B2 (en) 2006-09-05 2012-11-02 Ip-10 based immunological monitoring

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200601145 2006-09-05
DKPA200601145 2006-09-05
DKPA200700262 2007-02-20
DKPA200700262 2007-02-20
PCT/DK2007/000399 WO2008028489A2 (en) 2006-09-05 2007-09-05 Ip-i0 based immunological monitoring

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012244350A Division AU2012244350B2 (en) 2006-09-05 2012-11-02 Ip-10 based immunological monitoring

Publications (2)

Publication Number Publication Date
AU2007294293A1 AU2007294293A1 (en) 2008-03-13
AU2007294293B2 true AU2007294293B2 (en) 2013-06-27

Family

ID=38716188

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007294293A Active AU2007294293B2 (en) 2006-09-05 2007-09-05 Ip-10 based immunological monitoring

Country Status (17)

Country Link
US (2) US8026076B2 (enExample)
EP (4) EP2128612B1 (enExample)
JP (1) JP5805368B2 (enExample)
KR (1) KR101248491B1 (enExample)
CN (1) CN101523217B (enExample)
AT (1) ATE504000T1 (enExample)
AU (1) AU2007294293B2 (enExample)
BR (1) BRPI0714744B8 (enExample)
CA (1) CA2662429C (enExample)
DE (1) DE602007013620D1 (enExample)
DK (2) DK2128612T3 (enExample)
EA (1) EA020412B1 (enExample)
IN (1) IN2015DN03125A (enExample)
PL (1) PL2128612T3 (enExample)
PT (1) PT2128612E (enExample)
WO (1) WO2008028489A2 (enExample)
ZA (1) ZA200902297B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0722105D0 (en) 2007-11-10 2007-12-19 Sec Dep For Environment Food A Antigens
MX2010014556A (es) * 2008-06-25 2011-07-28 Baylor Res Inst Firma transcripcional de sangre por infeccion de mycobacterium tuberculosis.
CN102105786B (zh) * 2008-07-25 2014-10-29 赛乐思迪斯有限公司 诊断方法
CN102246040B (zh) * 2008-12-15 2014-11-05 安特鲁姆生物技术（私人）有限公司 用于诊断结核病的方法和装置
GB0906215D0 (en) 2009-04-09 2009-05-20 Lalvani Ajit Diagnostic test
DK2365332T3 (da) * 2010-03-10 2013-08-26 Pasteur Institut HMGB1- og anti-HMGB1-antistoffer i HIV-inficerede patienter, især med neurologiske lidelser
US20130078657A1 (en) * 2010-05-04 2013-03-28 Hvidovre Hospital Hyperthermia augmented in-vitro immune recognition
WO2012076020A1 (en) * 2010-12-09 2012-06-14 Hvidovre Hospital A method for generating, storing, transporting, eluting and detecting clinical relevant information in plasma using filter paper
WO2012139591A1 (en) 2011-04-13 2012-10-18 Hvidovre Hospital Monitoring liver fibrosis in a hepatitis c infected patient
EP2702076A1 (en) * 2011-04-29 2014-03-05 Bristol-Myers Squibb Company Ip-10 antibody dosage escalation regimens
CN103122033B (zh) * 2011-11-21 2015-08-19 厦门大学 一种嵌合重组抗原及其用途
WO2013087917A1 (en) * 2011-12-15 2013-06-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for diagnosing latent tuberculosis infection
ES2886979T3 (es) 2012-02-09 2021-12-21 Memed Diagnostics Ltd Distintivos y determinantes para diagnosticar infecciones y métodos para usarlos
WO2013168876A1 (ko) 2012-05-11 2013-11-14 가톨릭대학교 산학협력단 이식 후 면역 상태를 모니터링 하는 키트 및 이를 이용한 면역 상태의 모니터링 방법
JP6102438B2 (ja) 2012-05-30 2017-03-29 三菱化学株式会社 軸受部材、端部部材、感光体ドラムユニット、プロセスカートリッジ、及び軸受部材の製造方法
JP6020237B2 (ja) 2013-02-15 2016-11-02 三菱化学株式会社 軸受部材、端部部材、感光体ドラムユニット、及び軸受部材の製造方法
WO2015038624A1 (en) 2013-09-10 2015-03-19 Immusant, Inc. Dosage of a gluten peptide composition
KR101542510B1 (ko) 2014-01-15 2015-08-18 대한민국 초기 hiv-1 감염자에서 급속한 aids 질환 진행을 예측하기 위한 ip-10의 용도
RU2016137685A (ru) * 2014-02-26 2018-03-29 Стелленбос Юниверсити Способ диагностики туберкулеза
KR101590324B1 (ko) * 2014-04-24 2016-02-01 연세대학교 산학협력단 향상된 결핵 진단 방법
WO2015164747A1 (en) * 2014-04-24 2015-10-29 Immusant, Inc. Methods for diagnosing celiac disease using circulating cytokines/chemokines
EP3180621B1 (en) 2014-08-14 2020-04-01 Memed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
KR101748296B1 (ko) 2014-09-04 2017-06-19 연세대학교 산학협력단 마이코박테리움 압세수스 복합체 감염 폐질환 진단용 바이오마커 조성물
US10370718B2 (en) 2014-09-29 2019-08-06 Immusant, Inc. Use of HLA genetic status to assess or select treatment of celiac disease
EP3221344A2 (en) 2014-11-21 2017-09-27 Immusant Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
CN111624345A (zh) 2014-12-11 2020-09-04 米密德诊断学有限公司 用于诊断多种感染的标记组合及其使用方法
CN104897893A (zh) * 2015-06-10 2015-09-09 复旦大学附属华山医院 一种基于结核特异性il-31检测的诊断结核分枝杆菌感染的试剂盒
IL287757B (en) 2016-03-03 2022-07-01 Memed Diagnostics Ltd Analyzing rna for diagnosing infection type
CA3015046A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
CN109804245B (zh) * 2016-07-10 2022-10-25 米密德诊断学有限公司 感染的早期诊断
EP4141448A1 (en) 2016-07-10 2023-03-01 MeMed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
WO2018060999A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
CN108548917B (zh) * 2018-03-01 2021-07-06 广州市雷德生物科技有限公司 一种记忆性免疫细胞的检测体系及其应用
WO2020127908A2 (en) 2018-12-20 2020-06-25 Lophius Biosciences Gmbh Method of detecting infection with pathogens causing tuberculosis
WO2021255237A1 (en) 2020-06-19 2021-12-23 Mikrogen Gmbh Method of detecting infection with pathogens causing tuberculosis
WO2022169842A1 (en) * 2021-02-02 2022-08-11 Revelation Biosciences, Inc. Rapid detection kits and methods for diagnosing infections of the respiratory tract
WO2022240887A1 (en) * 2021-05-10 2022-11-17 Icahn School Of Medicine At Mount Sinai Methods for detecting and staging cellular viral immune responses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038201A1 (en) * 2002-01-22 2004-02-26 Whitehead Institute For Biomedical Research Diagnostic and therapeutic applications for biomarkers of infection
WO2006122050A2 (en) * 2005-05-05 2006-11-16 The Government Of The United States Of America, As Represented By The Secretary Methods and compositions for detecting immune responses
WO2007039400A1 (en) * 2005-09-27 2007-04-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of diagnosis of tuberculosis related immune restoration syndrome (irs)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777130A (en) * 1984-12-05 1988-10-11 Andra Biologicals Isolation of mycobacterial a 60 antigen for diagnostic purposes
EP1200466A2 (en) * 1999-07-13 2002-05-02 Statens Serum Institut Tuberculosis vaccine and diagnostics based on the mycobacterium tuberculosisesat-6 gene family
US7897357B2 (en) * 2000-10-18 2011-03-01 The United States Of America As Represented By The Secretary Of The Navy Assay for detecting immune responses involving antigen specific cytokine and/or antigen specific cytokine secreting T-cells
WO2003063759A2 (en) * 2002-01-31 2003-08-07 Peptor Ltd. Hsp peptides and analogs for modulation of immune responses via antigen presenting cells
AU2002952548A0 (en) 2002-11-08 2002-11-21 Cellestis Limited Diagnostic assay
WO2005012907A1 (en) * 2003-08-01 2005-02-10 Renovar, Inc. Systems and methods for characterizing kidney diseases
US7575862B2 (en) * 2003-12-09 2009-08-18 Asiagen Corporation Assay systems, kits and methods for detecting microorganisms
GB2427471B (en) 2004-03-04 2009-07-22 Laura Manuelidis Pre-symptomatic markers for diseases associated with transmissable spongiform encephalopaties
US20060051358A1 (en) * 2004-05-24 2006-03-09 Baylor Research Institute Immune response assessment method
US7332294B2 (en) * 2004-08-17 2008-02-19 University Health Network CXCL10-based diagnosis and treatment of respiratory illnesses
CA2478138A1 (en) 2004-08-17 2006-02-17 University Health Network Cxcl10-based diagnosis and treatment of respiratory illnesses
EP1994409A2 (en) * 2006-03-14 2008-11-26 Oregon Health and Science University Methods for producing an immune response to tuberculosis
CN1866023B (zh) * 2006-05-25 2010-11-03 上海市肺科医院 一种同步检测多种结核杆菌特异性分泌抗原的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038201A1 (en) * 2002-01-22 2004-02-26 Whitehead Institute For Biomedical Research Diagnostic and therapeutic applications for biomarkers of infection
WO2006122050A2 (en) * 2005-05-05 2006-11-16 The Government Of The United States Of America, As Represented By The Secretary Methods and compositions for detecting immune responses
WO2007039400A1 (en) * 2005-09-27 2007-04-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of diagnosis of tuberculosis related immune restoration syndrome (irs)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Diaz-Mitoma F et al, Journal of Clinical Virology, 2004, 31(2):100-112 *

Also Published As

Publication number Publication date
US20120015386A1 (en) 2012-01-19
BRPI0714744B1 (pt) 2018-10-16
EP2128612A3 (en) 2009-12-09
PL2128612T3 (pl) 2011-09-30
IN2015DN03125A (enExample) 2015-10-02
DK2261658T3 (en) 2015-04-27
WO2008028489A2 (en) 2008-03-13
BRPI0714744A8 (pt) 2016-04-05
KR20090074026A (ko) 2009-07-03
ATE504000T1 (de) 2011-04-15
US20100086950A1 (en) 2010-04-08
EA020412B1 (ru) 2014-11-28
EP2261658A2 (en) 2010-12-15
EP2128612A2 (en) 2009-12-02
US8026076B2 (en) 2011-09-27
BRPI0714744B8 (pt) 2021-07-27
JP5805368B2 (ja) 2015-11-04
CN101523217A (zh) 2009-09-02
DK2128612T3 (da) 2011-07-18
EP2059816A2 (en) 2009-05-20
ZA200902297B (en) 2015-10-28
DE602007013620D1 (de) 2011-05-12
WO2008028489A3 (en) 2008-05-15
BRPI0714744A2 (pt) 2013-05-07
EP2261658B1 (en) 2015-01-28
PT2128612E (pt) 2011-07-06
CN101523217B (zh) 2014-03-19
EP2261658A3 (en) 2011-05-11
EA200970246A1 (ru) 2009-10-30
KR101248491B1 (ko) 2013-04-03
EP2128612B1 (en) 2011-03-30
CA2662429A1 (en) 2008-03-13
JP2010502200A (ja) 2010-01-28
AU2007294293A1 (en) 2008-03-13
EP2228651A1 (en) 2010-09-15
CA2662429C (en) 2016-06-28

Similar Documents

Publication Publication Date Title
AU2007294293B2 (en) Ip-10 based immunological monitoring
AU2012244350B2 (en) Ip-10 based immunological monitoring
Goletti et al. Can we predict tuberculosis cure? What tools are available?
Jamil et al. Interferonγ/IL10 ratio defines the disease severity in pulmonary and extra pulmonary tuberculosis
US20130338059A1 (en) Methods for Differentiating Between Disease States
US20140342936A1 (en) Methods and kits for diagnosing latent tuberculosis infection
Arrigucci et al. Active tuberculosis is characterized by highly differentiated effector memory Th1 cells
CN102246040A (zh) 用于诊断结核病的方法和装置
JP5258584B2 (ja) 臨床的相関
WO2008052566A1 (en) Ccl8 based immunological monitoring
WO2012167307A1 (en) Diagnosis of mycobacterial infection
WO2014140833A2 (en) Methods for differentiating between disease states
ES2364173T3 (es) Control inmunológico basado en ip-10.
US20130078657A1 (en) Hyperthermia augmented in-vitro immune recognition
Fu et al. Progress on the biomarkers for tuberculosis diagnosis
Chiacchio New molecular diagnostic and immunological tools for tuberculosis research

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE CO-INVETOR NAME FROM RAVN, PEMILLE TO RAVN, PERNILLE

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ: IP-10 BASED IMMUNOLOGICAL MONITORING.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: STATENS SERUN INSTITUT

Free format text: FORMER OWNER WAS: HVIDOVRE HOSPITAL